tetano
Editor, Senior Moderator
J Med Econ
. 2022 Jan 17;1-21.
doi: 10.1080/13696998.2022.2030148. Online ahead of print.
Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective
. 2022 Jan 17;1-21.
doi: 10.1080/13696998.2022.2030148. Online ahead of print.
Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective
Adrian Kilcoyne[SUP] 1 [/SUP], Edward Jordan[SUP] 1 [/SUP], Allen Zhou[SUP] 2 [/SUP], Kimberly Thomas[SUP] 2 [/SUP], Alicia N Pepper[SUP] 2 [/SUP], Dale Chappell[SUP] 1 [/SUP], Miyuru Amarapala[SUP] 1 [/SUP], Avery Hughes[SUP] 2 [/SUP], Melissa Thompson[SUP] 2 [/SUP]
Affiliations
- PMID: 35037816
- DOI: 10.1080/13696998.2022.2030148
Abstract
Aims: Estimate the clinical and economic benefits of lenzilumab plus standard of care (SOC) compared with SOC alone in the treatment of patients hospitalized with COVID-19 pneumonia from the United States (US) hospital perspective.
Materials and methods: A per-patient cost calculator was developed to report the clinical and economic benefits associated with adding lenzilumab to SOC in newly hospitalized COVID-19 patients over 28 days. Clinical inputs were based on the LIVE-AIR trial, including failure to achieve survival without ventilation (SWOV), mortality, time to recovery, intensive care unit (ICU) admission, and invasive mechanical ventilation (IMV) use. Base case costs included the anticipated list price of lenzilumab, drug administration, and hospital resource costs based on level of care required. A scenario analysis examined projected one-year rehospitalization costs.
Results: In the base case and all scenarios, lenzilumab plus SOC improved all specified clinical outcomes relative to SOC alone. Lenzilumab plus SOC resulted in estimated cost savings of $3,190 per patient in a population aged <85 years with C-reactive protein (CRP) levels <150 mg/L and receiving remdesivir (base case). Per-patient cost savings were observed in the following scenarios: 1) aged <85 years with CRP <150 mg/L, with or without remdesivir ($1,858); 2) Black and African American patients with CRP <150 mg/L ($13,154); and 3) Black and African American patients from the full population, regardless of CRP level ($2,763). In the full modified intent-to-treat population, an additional cost of $4,952 per patient was estimated. When adding rehospitalization costs to the index hospitalization, a total per-patient cost savings of $5,154 was estimated.
Conclusions: The results highlight the clinical benefits for SWOV, ventilator use, time to recovery, mortality, time in ICU, and time on IMV, in addition to an economic benefit from the US hospital perspective associated with adding lenzilumab to SOC for COVID-19 patients.
Keywords: CRP; GM-CSF; I; I00; I1; I15; I19; coronavirus; cytokine storm; economic analysis; hospital costs; invasive mechanical ventilation; lenzilumab; survival without ventilation; ventilator-free survival.
